title: Special report: cost-effectiveness studies of new hepatitis C treatments.
authors.forename: David H
authors.initials: DH
authors.lastname: Mark
mesh_terms: D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination / Q000191:economics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics; D006575:Heterocyclic Compounds, 3-Ring / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D063868:Patient Outcome Assessment; D011480:Protease Inhibitors / Q000191:economics* / Q000627:therapeutic use; D013449:Sulfonamides / Q000191:economics* / Q000627:therapeutic use; D014542:Uridine Monophosphate / Q000031:analogs & derivatives / Q000191:economics* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D006575:Heterocyclic Compounds, 3-Ring; D011480:Protease Inhibitors; D013449:Sulfonamides; D014542:Uridine Monophosphate